{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T10:28:48Z","timestamp":1787048928974,"version":"build-2736575974"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T00:00:00Z","timestamp":1762732800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T00:00:00Z","timestamp":1762732800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Res"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1038\/s41390-025-04482-3","type":"journal-article","created":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T16:39:39Z","timestamp":1762792779000},"page":"2669-2679","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Saccharomyces boulardii\u2019s impact on pediatric diarrhea-predominant irritable bowel syndrome: animal model findings"],"prefix":"10.1038","volume":"99","author":[{"given":"Xinyu","family":"Jin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piao","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjuan","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinrong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weisong","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danrong","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,10]]},"reference":[{"key":"4482_CR1","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1097\/MED.0000000000000523","volume":"27","author":"A Canakis","year":"2020","unstructured":"Canakis, A., Haroon, M. & Weber, H. C. Irritable bowel syndrome and gut microbiota. Curr. Opin. Endocrinol. Diabetes Obes. 27, 28\u201335 (2020).","journal-title":"Curr. Opin. Endocrinol. Diabetes Obes."},{"key":"4482_CR2","doi-asserted-by":"publisher","DOI":"10.1111\/nmo.14756","volume":"36","author":"M Khasawneh","year":"2024","unstructured":"Khasawneh, M. et al. Utility of irritable bowel syndrome subtypes and most troublesome symptom in predicting disease impact and burden. Neurogastroenterol. Motil. 36, e14756 (2024).","journal-title":"Neurogastroenterol. Motil."},{"key":"4482_CR3","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1002\/iid3.348","volume":"8","author":"G Chao","year":"2020","unstructured":"Chao, G. & Zhang, S. The characteristics of intestinal flora of IBS-D with different syndromes. Immun. Inflamm. Dis. 8, 615\u2013628 (2020).","journal-title":"Immun. Inflamm. Dis."},{"key":"4482_CR4","doi-asserted-by":"publisher","first-page":"2369","DOI":"10.3390\/microorganisms11102369","volume":"11","author":"M Napolitano","year":"2023","unstructured":"Napolitano, M. et al. Gut dysbiosis in irritable bowel syndrome: a narrative review on correlation with disease subtypes and novel therapeutic implications. Microorganisms 11, 2369 (2023).","journal-title":"Microorganisms"},{"key":"4482_CR5","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1099\/jmm.0.001758","volume":"72","author":"WX Zhang","year":"2023","unstructured":"Zhang, W. X., Shi, L. B., Zhou, M. S., Wu, J. & Shi, H. Y. Efficacy of probiotics, prebiotics, and synbiotics in irritable bowel syndrome: a systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials. J. Med. Microbiol. 72, 798\u2013809 (2023).","journal-title":"J. Med. Microbiol."},{"key":"4482_CR6","doi-asserted-by":"publisher","unstructured":"Shin, A. et al. Microbiota-short chain fatty acid relationships and microbial substrate preferences vary across the spectrum of irritable bowel syndrome (IBS). medRxiv. 2024, 01 (Preprint) https:\/\/doi.org\/10.1101\/2024.01.31.24302084 (2024).","DOI":"10.1101\/2024.01.31.24302084"},{"key":"4482_CR7","doi-asserted-by":"publisher","first-page":"2558","DOI":"10.3390\/jcm12072558","volume":"12","author":"SD Shaikh","year":"2023","unstructured":"Shaikh, S. D., Sun, N., Canakis, A., Park, W. Y. & Weber, H. C. Irritable bowel syndrome and the gut microbiome: a comprehensive review. J. Clin. Med 12, 2558 (2023).","journal-title":"J. Clin. Med"},{"key":"4482_CR8","doi-asserted-by":"publisher","first-page":"e00658","DOI":"10.14309\/ctg.0000000000000658","volume":"15","author":"BY Wu","year":"2024","unstructured":"Wu, B. Y. et al. Mucosa-associated microbiota dysbiosis in the terminal ileum correlates with bowel symptoms in diarrhea-predominant irritable bowel syndrome. Clin. Transl. Gastroenterol. 15, e00658 (2024).","journal-title":"Clin. Transl. Gastroenterol."},{"key":"4482_CR9","doi-asserted-by":"publisher","first-page":"S56","DOI":"10.1097\/MCG.0000000000000418","volume":"49","author":"Y Ringel","year":"2015","unstructured":"Ringel, Y. & Ringel-Kulka, T. The intestinal microbiota and irritable bowel syndrome. J. Clin. Gastroenterol. 49, S56\u2013S59 (2015).","journal-title":"J. Clin. Gastroenterol."},{"key":"4482_CR10","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1159\/000528954","volume":"41","author":"LM Bustos Fern\u00e1ndez","year":"2023","unstructured":"Bustos Fern\u00e1ndez, L. M., Man, F. & Lasa, J. S. Impact of Saccharomyces boulardii CNCM I-745 on bacterial overgrowth and composition of intestinal microbiota in diarrhea-predominant irritable bowel syndrome patients: results of a randomized pilot study. Dig. Dis. 41, 798\u2013809 (2023).","journal-title":"Dig. Dis."},{"key":"4482_CR11","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1007\/s00284-020-02053-9","volume":"77","author":"K Ka\u017amierczak-Siedlecka","year":"2020","unstructured":"Ka\u017amierczak-Siedlecka, K., Ruszkowski, J., Fic, M., Folwarski, M. & Makarewicz, W. Saccharomyces boulardii CNCM I-745: a non-bacterial microorganism used as probiotic agent in supporting treatment of selected diseases. Curr. Microbiol. 77, 1987\u20131996 (2020).","journal-title":"Curr. Microbiol."},{"key":"4482_CR12","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s40801-024-00424-3","volume":"11","author":"BB Pal","year":"2024","unstructured":"Pal, B. B. et al. Effectiveness of Saccharomyces boulardii CNCM I-745 in adult Indian patients with diarrhoea: a real-world, multicentre, retrospective, comparative study. Drugs Real World Outcomes 11, 309\u2013316 (2024).","journal-title":"Drugs Real World Outcomes"},{"key":"4482_CR13","volume":"15","author":"S Gopalan","year":"2023","unstructured":"Gopalan, S. et al. Unique properties of yeast probiotic Saccharomyces boulardii CNCM I-745: a narrative review. Cureus 15, e46314 (2023).","journal-title":"Cureus"},{"key":"4482_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.curtheres.2023.100721","volume":"99","author":"GM Ahlawat","year":"2023","unstructured":"Ahlawat, G. M. & Singh, P. K. Methods of determining irritable bowel syndrome and efficiency of probiotics in treatment: a review. Curr. Ther. Res. Clin. Exp. 99, 100721 (2023).","journal-title":"Curr. Ther. Res. Clin. Exp."},{"key":"4482_CR15","doi-asserted-by":"publisher","first-page":"e76","DOI":"10.3928\/00904481-20140325-08","volume":"43","author":"A Chogle","year":"2014","unstructured":"Chogle, A., Mintjens, S. & Saps, M. Pediatric IBS: an overview on pathophysiology, diagnosis and treatment. Pediatr. Ann. 43, e76\u2013e82 (2014).","journal-title":"Pediatr. Ann."},{"key":"4482_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2022.106291","volume":"181","author":"Y Gu","year":"2022","unstructured":"Gu, Y. et al. Saccharomyces boulardii, a yeast probiotic, inhibits gut motility through upregulating intestinal serotonin transporter and modulating gut microbiota. Pharm. Res. 181, 106291 (2022).","journal-title":"Pharm. Res."},{"key":"4482_CR17","doi-asserted-by":"publisher","first-page":"e13985","DOI":"10.1111\/nmo.13985","volume":"33","author":"M Constante","year":"2021","unstructured":"Constante, M. et al. Saccharomyces boulardii CNCM I-745 modulates the microbiota-gut-brain axis in a humanized mouse model of Irritable Bowel Syndrome. Neurogastroenterol. Motil. 33, e13985 (2021).","journal-title":"Neurogastroenterol. Motil."},{"key":"4482_CR18","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1111\/apt.15001","volume":"48","author":"AC Ford","year":"2018","unstructured":"Ford, A. C. et al. Systematic review with meta-analysis: the efficacy of prebiotics, probiotics, synbiotics and antibiotics in irritable bowel syndrome. Aliment. Pharmacol. Ther. 48, 1044\u20131060 (2018).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"4482_CR19","first-page":"CD013095","volume":"2018","author":"LA Barajas-Nava","year":"2018","unstructured":"Barajas-Nava, L. A., Consuelo S\u00e1nchez, A., Castilla-Peon, M. F., Pizarro-Castellanos, M. P. & Vazquez Frias, R. Probiotics for the treatment of irritable bowel syndrome in children. Cochrane Database Syst. Rev. 2018, CD013095 (2018).","journal-title":"Cochrane Database Syst. Rev."},{"key":"4482_CR20","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.3389\/fmicb.2019.01894","volume":"10","author":"Y Gu","year":"2019","unstructured":"Gu, Y. et al. The potential role of gut mycobiome in irritable bowel syndrome. Front. Microbiol. 10, 1894 (2019).","journal-title":"Front. Microbiol."},{"key":"4482_CR21","doi-asserted-by":"publisher","DOI":"10.1128\/mSystems.01215-21","volume":"6","author":"J Phan","year":"2021","unstructured":"Phan, J. et al. Alterations in gut microbiome composition and function in irritable bowel syndrome and increased probiotic abundance with daily supplementation. mSystems 6, e0121521 (2021).","journal-title":"mSystems"},{"key":"4482_CR22","doi-asserted-by":"publisher","first-page":"155","DOI":"10.3390\/nu17010155","volume":"17","author":"MJ Garc\u00eda Mansilla","year":"2024","unstructured":"Garc\u00eda Mansilla, M. J. et al. Exploring gut microbiota imbalance in irritable bowel syndrome: potential therapeutic effects of probiotics and their metabolites. Nutrients 17, 155 (2024).","journal-title":"Nutrients"},{"key":"4482_CR23","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.3390\/nu11092048","volume":"11","author":"HF Dale","year":"2019","unstructured":"Dale, H. F., Rasmussen, S. H., Asiller, \u00d6\u00d6 & Lied, G. A. Probiotics in irritable bowel syndrome: an up-to-date systematic review. Nutrients 11, 2048 (2019).","journal-title":"Nutrients"},{"key":"4482_CR24","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.jand.2019.05.015","volume":"120","author":"L Wang","year":"2020","unstructured":"Wang, L. et al. Gut microbial dysbiosis in the irritable bowel syndrome: a systematic review and meta-analysis of case-control studies. J. Acad. Nutr. Diet. 120, 565\u2013586 (2020).","journal-title":"J. Acad. Nutr. Diet."},{"key":"4482_CR25","volume":"24","author":"W Jia","year":"2025","unstructured":"Jia, W. et al. Sodium Butyrate Promotes Enteric Glial Cells Neurogenesis by Inhibiting Kdm2a and Inducing Klf4 Expression. J. Pediatr. Surg. 24, 162428 (2025).","journal-title":"J. Pediatr. Surg."},{"key":"4482_CR26","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.3390\/antibiotics10091101","volume":"10","author":"R Gresse","year":"2021","unstructured":"Gresse, R. et al. Saccharomyces Cerevisiae var boulardii CNCM I-1079 reduces expression of genes involved in inflammatory response in porcine cells challenged by enterotoxigenic E. Coli and influences bacterial communities in an in vitro model of the weaning piglet colon. Antibiotics 10, 1101 (2021).","journal-title":"Antibiotics"},{"key":"4482_CR27","doi-asserted-by":"publisher","first-page":"e0181863","DOI":"10.1371\/journal.pone.0181863","volume":"12","author":"P Brun","year":"2017","unstructured":"Brun, P. et al. Saccharomyces boulardii CNCM I-745 supplementation reduces gastrointestinal dysfunction in an animal model of IBS. PloS one 12, e0181863 (2017).","journal-title":"PloS one"},{"key":"4482_CR28","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.578386","volume":"12","author":"F Cristofori","year":"2021","unstructured":"Cristofori, F. et al. Anti-inflammatory and immunomodulatory effects of probiotics in gut inflammation: a door to the body. Front. Immunol. 12, 578386 (2021).","journal-title":"Front. Immunol."},{"key":"4482_CR29","doi-asserted-by":"publisher","first-page":"78","DOI":"10.3390\/jof6020078","volume":"6","author":"P Pais","year":"2020","unstructured":"Pais, P., Almeida, V., Y\u0131lmaz, M. & Teixeira, M. C. Saccharomyces boulardii: what makes it tick as successful probiotic?. J. Fungi 6, 78 (2020).","journal-title":"J. Fungi"},{"key":"4482_CR30","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1136\/gutjnl-2016-313425","volume":"66","author":"M Camilleri","year":"2017","unstructured":"Camilleri, M. & Boeckxstaens, G. Dietary and pharmacological treatment of abdominal pain in IBS. Gut 66, 966\u2013974 (2017).","journal-title":"Gut"},{"key":"4482_CR31","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1053\/j.gastro.2023.07.018","volume":"165","author":"VC Goodoory","year":"2023","unstructured":"Goodoory, V. C. et al. Efficacy of probiotics in irritable bowel syndrome: systematic review and meta-analysis. Gastroenterology 165, 1206\u20131218 (2023).","journal-title":"Gastroenterology"},{"key":"4482_CR32","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.jnutbio.2018.08.005","volume":"61","author":"A Rodr\u00edguez-Nogales","year":"2018","unstructured":"Rodr\u00edguez-Nogales, A. et al. Intestinal anti-inflammatory effect of the probiotic Saccharomyces boulardii in DSS-induced colitis in mice: impact on microRNAs expression and gut microbiota composition. J. Nutr. Biochem. 61, 129\u2013139 (2018).","journal-title":"J. Nutr. Biochem."},{"key":"4482_CR33","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1038\/s41575-023-00794-z","volume":"20","author":"HM Staudacher","year":"2023","unstructured":"Staudacher, H. M., Black, C. J., Teasdale, S. B., Mikocka-Walus, A. & Keefer, L. Irritable bowel syndrome and mental health comorbidity-approach to multidisciplinary management. Nat. Rev. Gastroenterol. Hepatol. 20, 582\u2013596 (2023).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"4482_CR34","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s40272-022-00536-9","volume":"25","author":"R V\u00e1zquez-Frias","year":"2023","unstructured":"V\u00e1zquez-Frias, R. et al. Efficacy and safety of the adjuvant use of probiotic Bacillus clausii strains in pediatric irritable bowel syndrome: a randomized, double-blind, placebo-controlled study. Paediatr. Drugs 25, 115\u2013126 (2023).","journal-title":"Paediatr. Drugs"},{"key":"4482_CR35","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1007\/s12519-022-00516-6","volume":"18","author":"S Fatahi","year":"2022","unstructured":"Fatahi, S. et al. Effects of probiotic supplementation on abdominal pain severity in pediatric patients with irritable bowel syndrome: a systematic review and meta-analysis of randomized clinical trials. World J. Pediatr. 18, 320\u2013332 (2022).","journal-title":"World J. Pediatr."}],"container-title":["Pediatric Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41390-025-04482-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41390-025-04482-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41390-025-04482-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T10:00:56Z","timestamp":1787047256000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41390-025-04482-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,10]]},"references-count":35,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["4482"],"URL":"https:\/\/doi.org\/10.1038\/s41390-025-04482-3","relation":{},"ISSN":["0031-3998","1530-0447"],"issn-type":[{"value":"0031-3998","type":"print"},{"value":"1530-0447","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,10]]},"assertion":[{"value":"16 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"Consent has been obtained from the patient and informed consent has been signed.","order":2,"name":"Ethics","label":"Consent statement","group":{"name":"EthicsHeading","label":"Ethics"}}]}}